OrthoPediatrics Corp

KIDS remains in a Stage 4 decline with confirmed lower highs and lows and price below all key moving averages; there are no signs of selling exhaustion, volume and volatility support further downside, and both medium- and short-term signals align with a bearish continuation, favoring selling on breakdown into the next support area.

• ↑Q2 2026 revenue grew 15% YoY to $70.5M, led by trauma and deformity products.
• ↑Launched 3P Pediatric Plating Platform Hip System; management expects revenue to build further.
• ↓Net losses persist; weak profitability metrics raise questions on long-term returns.